drugset / Trial / NCT02789111

Trial of Alvimopan in Major Spine Surgery

NCT02789111

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The Investigator has chosen to study the reconstructive spinal surgery patient population because it is believed that the use of alvimopan in these patients at the University of Virginia will give the scientific community significant insight into the broader applicability of this drug into other surgical populations, the impact of this drug on the perception of pain (as opposed to simply the consumption of opioids), and its impact on total hospital charges, resource utilization, and functional outcomes.

Timeline

Start
2016-06-01
Primary completion
2018-12-01
Completion
2018-12-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alvimopan Small molecule 12 mg Oral

Indications